[Doxazosine associated to renin-angiotensin blockers and calcioantagonists in chronic renal failure patients].
OBJECTIVE
To evaluate the safety and effectiveness of the alfa-blocker doxazosin GITS in CRF patients.


METHODS
The study recruited 203 CRF patients (creatinine > 1,4 mg/dl for males, creatinine > 1,2 mg/dl for females, or creatinine clearance < 80 ml/min). All patients were receiving ACE inhibitores (63.4%) or angiotensin II antagonist (36.6%) therapy but they had higher blood pressure than recommended for CRF (130/85 mmHg). Patients were clinically evaluated 1, 3 and 6 moths after starting treatment with lercanidipine (10 mg once daily). Patients with high blood pressure in spite of combined therapy with two drugs added doxazosin GITS 4-8 mg once daily to treatment.


RESULTS
57 patients rendered evaluable for the study (age 64.8 +/- 12.7 years, 47.4% males and 52.6 females). BP significantly decrease from 164 +/- 17/92 +/- 9 mmHg to 135 +/- 13/78 +/- 8 mmHg. 67.6% patients showed a significant BP reduction and 32.4% gets optimal BP control (< 130/85 mmHg). Two patients (3.6%) showed untoward effects. No biochemical changes were detected.


CONCLUSIONS
Doxazosin showed a good antihypertensive effect in CRF patients when used as third drug in resistant severe hypertension. It has a good tolerability profile and showed a neutral profile on biochemical parameters.
Robles
N R
NR
Hospital Infanta Cristina, Badajoz. nroblesp@meditex.es
Gómez Campderá
F
F
Ocón
I
I
Manjón
M
M
Pastors
L
L
Herrera
J
J
Villatoro
J
J
Calls
I
I
Torrijos
I
I
Rodríguez Villareal
I
I
Rodríguez Martínez
M A
MA
Méndez
M L
ML
Morey
A
A
Martínez Fernández
I
I
Marco
I
I
Liébana
A
A
Rincón
B
B
Tornero
F
F
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy*; D008297:Male
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017292:Doxazosin